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PAI-1  - Plasminogen activator inhibitor-1 
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APSAC - Anisoylated Plasminogen Streptokinase 
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 INTRODUCTION 
 Coronary heart disease has been defined as “Impairment 
of heart function due to inadequate blood flow to the heart 
compared to its needs, caused by obstructive changes in the 
coronary circulation to the heart”. 
 It is the cause of 25-30% of deaths in most of the 
industrialized countries. In India also it is a major public health 
problem.  
 It is aptly called by WHO as the modern epidemic. The 
increasing incidence of coronary heart disease may be a 
reflection of increased longevity, adoption of high fat diet, 
decreased exercise, made possible by increasing affluence. 
 It is not surprising to note that Sir. William Osler devoted 
only a few pages in his text book of medicine, published in 1982 
to the discussion of Acute myocardial infarction.  
 It was the brilliant work of Herrick in 1912, who 
performed autopsy on Acute myocardial infarction patients that 
put forward the new concept of thrombotic occlusion of 
coronary artery as the cause of downstream necrosis of heart 
muscle.  
 Definite proof for the above said concept came from 
angiographic studies performed during the early hours of the 
Acute event.2 
 This prompted scientists to systematically test the 
thrombolytic strategies to treat Acute myocardial infarction, 
opening the new era of thrombolytic therapy in acute 
myocardial infarction.  
 Scientists have developed many effective thrombolytic 
drugs like, streptokinase, recombinant tissue plasminogen 
activator (rt PA) Reteplase (rPA), Urokinase, APSAC (Anisoylated 
plasminoses streptokinase activator complex), etc. 
 Evidence for the use of thrombolytic therapy came from 
large multicentre studies3. GISSI and ISIS-2 confirmed 
reduction in mortality with the early use of streptokinase5.ISAM 
(Intravenous streptokinase in Acute myocardial infarction study 
group) also stands as a proof of efficacy of thrombolytic drugs to 
reduce mortality.  
 Success rate of thrombolysis and thus the overall 
reduction in mortality is different among different agents used6. 
The GUSTO-1 trial showed a 30 days mortality of 6.3% for 
accelerated t-PA versus 7.4% for streptokinase with intravenous 
heparin.  
 But because of the prohibitive cost of tPA, streptokinase 
became sheet anchor for thrombolytic therapy in Government 
Royapettah Hospital. Thrombolytic therapy has revolutionised 
the management of Acute myocardial infarction7. 
 GUSTO angiographic substudy showed a success rate of 
54% at 90 minutes using strephokinase and Heparin.  
 Thrombolytic therapy has been consistently proven to 
reduce the mortality and morbidity. Inspite of this it has been 
recognized that thrombolytic therapy has failed in a significant 
population. There is lot of room for improvement. We need to 
identify the factors that are responsible for failure of 
thrombolysis.  
 In this background, we decided to look into over own 
particulars who receive streptokinase for Acute myocardial 
infarction, in the coronary care unit of Government Royapettah 
Hospital.  
  
AIM OF STUDY 
1. To find out the overall success rate of thrombolysis in 
the coronary care unit of Government Royapettah 
Hospital. 
2. To find out whether the following parameters influence 
the outcome of thrombolysis.  
a. Age 
b. Sex 
c. Body mass Index 
d. Smoking status 
e. Alcohol intake 
f. Diabetes mellitus 
g. Systemic Hypertension 
h. Pre infarction Angina 
i. Time window 
j. Location of myocardial infarction 
REVIEW OF LITERATURE 
HISTORICAL PERSPECTIVE 
 Although the anginal syndrome was described in the 
1770’s it was not until 1912 that Sir James B. Herrick 
described acute myocardial infarction. 
 In the landmark paper, Herrick wrote “The clinical 
manifestation of coronary obstruction will evidently vary 
greatly… depending on the size, location and number of vessels 
occluded. The symptoms and end results must also be 
influenced by blood pressure, by the condition of myocardium 
not immediately affected by obstruction, and by the ability of 
the remaining vessels to properly carryout their work as 
determined by their health or disease”8. 
 Most of his observations hold good even after 90 years. 
 Levine published a book on coronary thrombosis in 1929. 
 Only after the classic angiographic study of De wood and 
colleagues from Spotane, who demonstrated thrombotic 
occlusion of coronary arteries in 87% of patients within 4 hours 
of symptom onset, medical community was convinced that the 
proximate cause of Acute myocardial infarction is coronary 
thrombosis2. 
PATHOPHYSIOLOGY OF ACUTE MYOCARDIAL INFARCTION 
 Coronary atherosclerosis is the underlying substrate in 
nearly all patients with Acute myocardial infarction.  
 The hallmark of atherosclerotic coronary artery disease is 
the fibrous plaque. It has a fibrous cap, composed of smooth 
muscle cells and matrix, which covers a variable amount of 
lipid core, cell debris, macrophages, which may be filled with 
lipid, often intermixed with variable number of T-lymphocytes.  
 Plaques are not uniform in their constitution. Plaque 
heterogeneity is important in that which plaque is prove to 
fissuring or cracking cannot be determined even by 
angiography. 
 Those plaques which have a thin fibrous cap, more 
number of macrophage and T cells, more lipid content and less 
number of smooth muscle cells are prove to rupture9. Smooth 
muscle cells appear to protect against plaque disruption, 
whereas macrophages and mononuclear cells, by elaborating 
proteolytic enzymes like matrix metallo proteinase, 
stromelysins, elastases tend to weaken the fibrous cap10. 
Mononuclear cells also elaborate monocyte chemotactic protein 
(MCP-1) which recruits more number of macrophages and 
mononuclear cells into the fibrous cap. 
WHAT PRECIPITATES PLAQUE DISRUPTION? 
 It is now proved beyond  doubt that acute myocardial 
infarction occurs as a result  of disruption of a coronary artery 
plaque at a site of high density of   inflammatory cells namely 
macrophages and T lymphocytes.  Thus acute myocardial 
infarction  can be thought of as resulting from acute 
exacerbation of a chronic inflammatory response. Precipitating  
factors work  by exacerbating  the inflammatory response and 
of increasing the physical focus impinging on coronary artery 
lesion  weakened by inflammation, leading to rupture.  
1. Infections 
 An association has been noted between Acute myocardial 
infarction and antecedent mild respiratory syndromes. 
 Increased antibody titre to C. pneumoniae have been 
associated with increased risk of acute myocardial infarctions11. 
 Evidence exists for the presence of C. Pneumoniae in 
atherosclerotic lesions. 
2. Emotional or Environmental stress 
 There was considerable higher incidence of Acute 
myocardial infarctions during scud missile attacks in the 
Gulfwar and Los Angeless earth Quake12,13. Sudden surges of 
epinephrine may be the culprit by increasing the myocardial 
oxygen demand and also increasing the platelet aggregability.  
3. Circadian and seasonal variation 
  Peak incidence of acute myocardial infarction is between 6 
AM and noon. Underlying mechanism is thought to be the 
diuranal variation in sympathetic nervous system activity and 
thrombotic tendency.  
 In the morning hours there is an enhanced platelet 
aggregability and a trough in intrinsic fibrinolytic activity. Other 
factors contributing are the increased heart rate and increased 
coronary artery tone in the morning. PAI-1 levels in blood is 
highest in the morning hours.  
THROMBUS FORMATION 
 Thrombus formation at the site of plaque disruption is the 
fundamental pathophysiological mechanism of unstable angina 
and acute myocardial infarctions.  
ROLE OF PLATELETS 
 This may be reviewed in 3 heading 
1. Platelet adhesions  
2. Platelet Activation with granular release 
3. Platelet aggregation 
PLATELET ADHESION 
  Platelets adhere to the subendothelial collagen 
immediately. Glycoprotein 1b on the platelet membrane links 
with Von Willebrand Factor (VWF) in the subendothelial 
collagen. The membrane receptor complex glycoprotein IIb / IIIa 
bind a number of relevant protein, including VWF, fibrinogen 
and fibronection. 
PLATELET ACTIVATION AND AGGREGATION 
 Activated platelets release a number of substances like 
serotonin, ADP, PDGF (Platelet derived growth factor), 
thrombospondin, VWF etc. 
 PDGF Plays a role in the proliferation and migration of 
smooth muscle cells after vessel damage. Released ADP binds 
to the specific receptors that change the conformation of Gp 
IIB/IIIa comoplex so that it binds VWF, fibrinogen, fibronectin, 
thus linking adjacent platelet into hemostatic plug.  
COAGULATION CASEADE 
 Coagulation caseade plays a critical role in secondary 
hematosis. Both intrinsic and extrinsic system take part in this 
process.  
SYSTEMIC FACTORS FAVORING THROMBOGENESIS 
1. Catecholamines 
 Circulating catecholamines increases the platelet 
aggregability and thrombin generation. 
 Smoking and emotional factors may be operating by 
increasing the catecholamines levels in blood.  
2. Elevated level of homocysteine 
 This is toxic to endothelium and it decreases the capacity 
of endothelium to make nitric oxide and includes endothelial 
dysfunction. 
3. Diabetes mellitus 
 Apart from accelerated atherosclerosis, platelet activity 
and coagulation are increased in diabetics suggesting that it is 
a prothrombotic state. PAI-I levels are also found to be higher in 
diabetics. 
4. Plasminogen activator inhibitor-1 (PAI-1) 
 High levels of PAI-I levels are associated with increased 
risk of Acute coronary syndromes.  
5. Elevated apoliporpotein (a) 
 May serve as a competitive inhibitor of plasminogen and 
cause a prothrombotic stage.  
6. Elevated fibrinogen and factor VII 
 Is yet another risk factor for thrombosis. Interestingly 
both are found to be elevated in advanced age, obesity, 
hyperlipidemia, diabetes, smoking and emotional stress. 
FIBRINOLYSIS 
 Fibrinolysis starts at the same time of thrombogenesis 
because elements of the fibrinolytic system are incorporated 
into the fibrin thrombus as it forms.  
COMPONENTS OF FIBRINOLYTIC SYSTEM 
1. Plasminogen and plasmin 
 Plasminogen is a single chain glycoprotein synthesised 
primarily by liver. This is the precursor of the chief proteolytic 
enzyme plasmin. This conversion is facilitated by the binding of 
plasminogen to fibrin (thrombus). Plasmin is capable of 
proteolysing not only fibrin but also other proteins like 
fibrinogen, coagulation factors V, VIII, and extracellular matrix 
protein.  
2. Plasminogen activators 
 Intrinsic activators of plasminogen are kallikrein and 
factor XIIa which are direct activators.  
 Extrinsic activators are tissue type palsminogen activator 
(t-PA), High molecular weight- two chain urokinase, and low 
molecular weight two chain urokinase. 
Exogenous activators 
 Are used therapeutically in Acute myocardial infarction, 
Streptokinase, APSAC, belong to this category. 
TISSUE TYPE PLASMINOGEN ACTIVATOR  
 t-PA is synthesised predominantly by vascular endothelial 
cells. It is a serine protease. 
 In the absence of fibrin, t-PA has little activity. Therefore 
t-PA mediated activation of Plasminogen in plasma is minimal. 
Both single chain and two chain form of t-PA have proteolytic 
activity that is enhanced several hundred fold in the presence of 
fibrin. 
 Free plasmin in the plasma is rapidly neutralised by CX2  
plasmin inhibitor where as fibrin-bound plasmin is protected 
from X2- plasmin inhibitor.  
UROKINASE TYPE PLASMIN ACTIVATORS 
 Urokinase is a serine protease that is synthesised in the 
kidney as well as in endothelial cells and initially released as a 
single chain urokinase or single chain-PA. 
 Limited proteolysis by plasmin converts single chain-PA to 
high molecular weight two chain urokinase (HMW two chain 
UK). Like t-PA, HMW two chain UK also has relative fibrin 
selectivity but it is enhanced only 10 times by the presence of 
fibrin. 
ENDOGENOUS INHIBITORS OF FIBRINOLYSIS 
 These inhibitors of plasminogen activators and plasmin 
belongs to serpin family.  
Plasminogen Activator Inhibitor (PAI - 1) Sources 
 Endothelial cells, hepatocyte, smooth muscle cells and 
platelets. It is stored in platelet α - granules from which it can 
be readily released upon platelet activation. PAI-1 is the 
predominant inhibitor of t-PA and urokinase in human plasma. 
It accounts for approximately 60% of the total plasminogen 
activator inhibitory capacity of plasma.  
 Thrombin induces PAI-1 release from cultured human 
endothelial cells; so also endotoxin. During inflammatory states  
PAI-1 levels are increased.  
 There is a diuranal variation in the circulating levels of 
PAI-1 concentration which contribute to the clustering of Acute 
Myocardial Infarction episodes during morning hours as well as 
morning resistance to thrombolytic therapy.  
 PAI-2 is found in placental tissue, where it plays a role in 
hemostasis. 
ALPHA2-PLASMIN INHIBITOR 
 This single chain glycoprotein directly inhibits plasmin. It 
is synthesised and secreted from hepatocytes. It is also stored 
in platelet α granules. Alpha 2 plasmin inhibitor rapidly 
neutralizes free plasmin in plasma. Where as fibrin bound 
plasmin is protected from its action. Alpha-2 plasmin is 
incorporated into fibrin clots through cross-linking by factor 
XIIIa thereby preventing uncontrolled or premature fibrinolysis.  
PROTEIN C ACTIONS 
 It inhibits the release of PAI – 1 from endothelial cells and 
inactivates PAI – 1, factor Va, VIIa. 
REGULATION OF FIBRINOLYSIS 
 Net activation of plasminogen is the result of a delicate 
balance among activators and inhibitors and protease receptor 
on the cell surface. Regulation and control of fibrinolysis occurs 
at several levels. Secretion of plasminogen activator and also 
plasminogen activator inhibitor from endothelium enhancement 
of plasminogen activation by f-fibrin and plasmin inhibiton by 
alpha 2 antiplasmin inhibition. In addition certain cell types 
such as endothelial cells, monocytes and platelets have 
receptors for plasminogen and plasminogen activators which 
when occupied enhance plasminogen activation and localize 
plasmin activity to the cell surface. By modulating the 
expressing of these cell surface receptors, cellular regulation of 
fibrinolysis is possible.  
ACUTE MYOCARDIAL INFARCTION 
Symptoms 
 Prodromal symptoms are common, most of these 
symptoms are anginal or anginal like, hours or days before the 
acute cardiac event. 
 Retrosternal chest pain, associated with nausea, 
diaphoresis and dyspnoea is the cardinal symptoms. Pain may 
radiate to medial aspect of left arm or to both arms, other sites 
of radiation are neck or lower jaw, to epigastrium and back. 
 Duration should be more than 15 minutes, occasionally 
presenting symptoms may be syncope, acute confusion, 
agitation, stroke or palpitations. Approximately 23% of Acute 
myocardial infarction go unnoticed by the patient because of 
lack of symptoms. Elderly can present as congestive cardiac 
failure without any history of pain. 
Physical Findings 
 Patient may have an anxious look. Sweating may be 
excessive.  
 Pulse rate normal or increased. Persistent sinus 
tachycardia beyond the initial 12-24 hrs is predictive of high 
mortality rate.  
 In patients with acute inferior wall myocardial infarction 
upto 60% of patients will be having bradycardia in initial hours.  
Blood Pressure 
 Hypotension can occur in acute inferior wall infarction, 
with right ventricular involvement, and extensive anterior wall 
infarction with cardiogenic shock. Hypertension may be a 
feature of anterior wall acute myocardial infarction.  
JVP 
 Elevated JVP is a feature of major RV infarction. 
Prominent ‘a’ wave may occur because of the decreased 
compliance of right ventricle. Kussmaul sign may also be seen 
in right ventricular infarction. 
PRECORDIAL EXAMIANTION 
Palpation 
 Palpation in the left lateral position may reveal a diffuse 
apical impulse rather than a localized impulse. Apex may be 
dyskinetic also. Decreased compliance of left ventricle may give 
rise to presystolic expansion of apex corresponding to the 
auscultatory S4. 
Auscultation 
 First and second heart sounds are often very soft because  
of decreased contractility, prolonged PR interval or both. 
 A fourth heart sound is often audible. Third heart sound 
is heard in probably only about 15-20% of acute myocardial 
infarction patients.  
 Ischemia of posteromedial papillary muscle can manifest 
as a crescendo decrescendo mid systolic murmur of mitral 
regurgitation. This murmur usually disappear after the first 12-
24 hrs if it is soft. But a loud or moderate intensity murmur 
may persist much longer or may be permanent 
DIAGNOSIS 
Electrocardiography 
 Electrocardiographic criteria for diagnosing acute 
myocardial infarction are, in presence of chest pain any one of 
the following.  
(i) New or presumably new Q waves (atleast-30ms wide 
and 0.20 mV deep) in atleast two leads in any of the 
following groups a) lead II, III, avF b) leads V1-V6 C) 
leads I & avL. 
(ii) New or presumably new ST segment elevation or 
depression ≥ 0.10 mV measured 0.02 sec. after J 
point in two contiguous leads of the above 
mentioned lead combination. 
(iii) New or presumably new complete LBBB. 
Enzymatic Criteria 
1. Serial increase and then decrease of plasma CK-MB 
with change of > 25% between two values.  
2. CK-MB > 10-13 U/L or > 5% of total CK activity. 
3. Increase in CK-MB activity > 50% between any two 
samples  separated by atleast 4 hours. 
4. If only a single sample available, CK-MB elevation > 
two fold.  
5. Beyond 72 hours, an elevation of Troponin T or 
Troponin I or LDH-1 > LDH-2. 
HEMODYNAMIC CLASSIFICATION OF AMI (KILLIP) 
 Killip classification is the most useful simple method to 
assign patients into hemodynamic classes.  
Class I 
 No evidence of heart failure. 85% of Acute myocardial 
infarction patients present in this class. 
Class II 
 Early evidence of heart failure manifested by, bibasilar 
rales (less than 50% of lung fields) 10% of people present in this 
category. 
Class III 
 Frank pulmonary odema. 
Class IV 
 Cardiogenic shock. Only 5% of people with Acute 
myocardial infarction presents in class III or IV category. 
MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION 
 Immediately begin continuous cardiac monitoring for 
patients with suspected ischemic type of chest pain and obtain 
intravenous access.  
 Administer morphine, oxygen, nitroglycerine and aspirin 
to patients without contraindication.  
THROMBOLYTIC THERAPY : INDICATIONS 
Class I 
1.  In the absence of contraindications fibrinolytic therapy 
should be administered to STEMI patients with symptom 
onset within the prior 12 hours and ST elevation greater 
than 0.1 mV in at least 2 contiguous precordial leads or 
at least 2 adjacent limb leads. 
2.  In the absence of contraindications, fibrinolytic therapy 
should be administered to STEMI patients with symptom 
onset within the prior 12 hours and new or presumably 
new LBBB. 
Class IIa 
1.  In the absence of contraindications, it is reasonable to 
administer fibrinolytic therapy to STEMI patients with 
symptoms onset within the prior 12 hours and 12 lead 
ECG findings consistent with a true posterior MI. 
2.  In the absence of contraindications, it is reasonable to 
administer fibrinolytic therapy to patients with symptoms 
of STEMI beginning within the prior 12 to 24 hours who 
have continuing ischemic symptoms and ST elevation 
greater than 0.1 mV in at least 2 contiguous precordial 
leads or at least 2 adjacent limb leads. 
Class III 
1.  Fibrinolytic therapy should not be administered to 
asymptomatic patients whose initial symptoms of STEMI 
began more than 24 hours earlier. 
2.  Fibrinolytic therapy should not be administered to 
patients whose 12-lead ECG shows only ST-segment 
depression except if a true posterior MI is suspected. 
CONTRAINDICATIONS 
Absolute Contraindications 
 Any prior intracranial Haemorrhage. 
 Known structural cerebral vascular lesions (eg. 
Arterio venous malformation). 
 Known malignant intracranial neoplasm (Primary or 
metastatic). 
 Ischemic stroke with in 3 months EXPECT acute 
ischemic stroke with in 3 hours. 
 Suspected aortic dissection.  
 Active bleeding or bleeding diathesis  (excluding 
menses). 
 Significant closed head or facial trauma within 3 
months. 
Relative Contraindications 
 History of chronic severe poorly controlled 
hypertension. 
 Severe uncontrolled hypertension on presentation 
(SBP > 180 or DBP > 110 mmHg). 
 History of prior ischemic stroke greater than 3 
months, dementia, or known intracranial pathology 
not covered in contraindications.  
 Traumatic or prolonged (> 10 min). CPR or major 
surgery (less than 3 week). 
 Recent (within 2-4 weeks) internal bleeding.  
 Non compressible vascular   punctures  
 For streptokinase / anistreplase prior exposure (> 5 
days ago) or prior allergic reaction to these agents 
 Pregnancy 
 Active peptic ulcer 
 Current use of anticoagulant the higher the INR, the 
higher the risk of bleeding.  
HISTORY OF THROMBOLYSIS 
 Human blood has long been known to contain fibrinolytic 
activity. Well over 110 years ago Denys and Zimmerman 
observed that the fibrin of human blood obtained from wet 
cupping dissolved in 12 to 24 hours. Dastre coined the term 
fibrinolysis. 
 The property of spontaneous thrombolysis was used by 
Yudin of Russia who used blood from fresh corpses (who were 
previously healthy; but died of accidents) for transfusion. 
 In 1933 Tillet and Garner at the John Hopkin’s medical 
school demonstrated that filtrates of broth cultures of certain 
strains of hemolytic streptococcus contained a substance 
capable of inciting rapid fibrinolysis of human plasma clots. 
They named it streptococcal fibrinolysis.  
 Christensen renamed it streptokinase in 1945. He 
demonstrated that SK activates an inactive precursor of a 
proteolytic enzyme, later found to be plasminogen.  
 Streptokinase was clinically used first in 1947 by Tillet 
and Sol sherry in a young man who developed loculated bloody 
effusion in the left pleural cavity following pneumonectomy. The 
response was dramatic in that all the loculation were broken 
down and a lysed coagulum was drained.  
 First clinical trial for acute myocardial infarction recruited 
24 patients and they found those treated early alter the onset of 
infarction did better than those treated late16. 
 But only in 1977 FDA approved streptokinase and 
urokinase for clinical use in USA. Which opened the new era of 
reperfusion therapy.  
THROMBOLYTIC DRUGS 
NON FIBRIN SELECTIVE AGENTS 
Streptokinase 
 It is a single chain polypeptide that lacks the serine 
residue required for enzymatic activity but it can activate 
plasminogen to plasmin after forming an equimolar complex 
with it. 
 Since it is not fibrin selective, extensive conversion of 
circulating plasminogen to plasmin occurs with subsequent 
depletion of fibrinogen, plasminogen and factors V and VIII from 
blood stream.  
 The accumulation of fibrin degradation products, 
depletion of circulating alpha 2 antiplasmin and 
hyperplasminemia that occur constitute a systemic lytic state. 
 Circulating half life of SK is 18-25 minutes. However the 
level of fibrinogen to less than 50% of baseline values persists 
for approximately 24 hours.  
 Antibodies to SK appear quickly and reaches high value 
by 5 days and remains above baseline for upto 30 months. So 
repeated administration is not recommended.  
Adverse Effects 
 Hypotension is the most common adverse effect which 
ranges from 10-40% of SK administrations. 
 Allergic reactions reported included fever, chills, urticaria, 
rash, flushing and muscle pain. 
 Minor bleeding can occur especially from vascular 
puncture and access site. Manual compression for 30 minutes 
or until bleeding stops is usually effective.  
Intracranial bleeding is the dreaded complication.  
Total stroke incidence in GISSI / International Trial was  
0.9%. In ISIS 3 trial it was 1%. 
Mode of Administration and Dosage 
1.5 million units of SK administrated over 1 hour is the 
standard regimen. More rapid administration can lead to 
hypotension and should be avoided. 
UROKINASE 
 This is an endogenous trypsin like enzyme. It is a direct 
plasminogen activator. It is present in urine and occurs in two 
forms in blood and tissues as a high molecular weight form and 
low molecular weight form. It is non fibrin selective, producing 
a systemic lytic state similar to that produced by SK. It is non 
immunogenic and can be administrated as an intravenous 
bolus or by infusion. 
 The recommended dose for Acute myocardial infarction is 
1,500,000 unit bolus followed by 1,500,000 units given over 90 
minutes.  
RELATIVELY FIBRIN SELECTIVE AGENTS 
Tissue plasminogen Activator (t-PA) 
 t-PA is an endogenous serine protease synthesised and 
secreted by human vascular endothelium and numerous other 
types of cells. Cloning and expression of t-PA gene in E-coli lead 
to the large scale production of recombinant t-PA since 1984. 
 Plasma T½ is only 5 minutes but fibrinolytic activity 
persists on and within clots for 7 hours. rt-PA is metabolised by 
liver. Plasminogen activator inhibitor-1 (PAI-1) rapidly 
inactivates t-PA. Infused rtPA rapidly saturates PAI-1 levels 
seen in blood. Other slow inhibitors of rtPA in blood are C1 
esterase inhibitor and alpha   2 antiplasmin.  
 rtPA is relatively fibrin specific, it has an affinity for fibrin 
bound plasminogen. But rtPA is also capable of depleting blood 
fibrinogen levels to as low as an 50% and elevating fibrinogen 
degradation products. It has no immunogenisity.  
Adverse Effects 
 Incidence of intracranial hemorrhage and stroke is 
slightly higher with rtPA than with SK. In GISSI / International 
trial it was 1.2%. In ISIS-3 it was 1.4% (Total stroke incidence) 
Dosage 
 Front loaded regimen is  associated with  91%. Patency 
rate at 90 minutes and it is now approved by FDA. Here 15 mg 
IV bolus followed by 50mg IV infusion over 30 minutes followed 
by 35 mg over next 60 minutes is given.  
EFFECTS OF THROMBOLYTIC THERAPY ON MORTALITY 
 Thrombolytic therapy reduces 35 day mortality by 21% 
compared with conventional therapy.  
 When used within the first hour of symptoms it serves 34 
lives per 1000 treated patients but it is reduced to 16 lives per 
1000 treated cases when used 7-12 hours after the onset of 
symptoms. 
CHOICE OF DRUG 
(30 day mortality rate from GUSTO Trial) 
S.No. Regimen Mortality % 
1. SK and Subcutaneous heparin 7.2% 
2. SK and Intravenous heparin 7.4% 
3. Accelerated rt-PA and Intravenous 
heparin 
6.3% 
4. Combination rt-PA and SK without 
Heparin 
7% 
 
 14% reduction in mortality rate was achieved with 
accelerated rtPA regimen versus SK strategies (p=0.001). 
 1 year follow up of GUSTO-1 trial showed that the 1% 
lower mortality rate compared with SK was maintained, which 
provided further evidence that rt-PA is more effective than SK. 
 Alteplase (rt-PA) may have the greatest benefit in patients 
with large infarction and appears to be a low risk of intracranial 
haemorrhage in younger patients who present early. SK 
appears to provide greater benefit in older patients with as 
smaller amount of myocardium at risk, who present later and 
those with a greater risk to intracranial haemorrhage.  
PATENCY OF INFARCT RELATED ARTERY 
Angiography assessment 
 TIMI grading is used to assess the angiographic patency17. 
Grade of 
Flow 
Definition 
0 Complete occlusion 
1 Penetration without perfusion. Coronary bed distal 
to occlusion fails to opacify completely. 
2. Partial perfusion. Full but slow opacification of 
coronary bed distal to occlusion 
3. Complete perfusion 
 The 90 minutes patency rate from GUSTO angiographic 
substudy was as follows; accelerated t-PA 81%. (54% grade III 
flow), combination treatment t-PA-SK 73% (38%- grade III flow) 
SK-IV Heparin 60% (32%-Grade III flow), SK- Subcutaneous 
heparin 54% (29% grade III flow)6,7. 
 This clearly shows rt-PA is more effective than SK in 
bringing out a successful thrombolysis.  
CLINICAL DETECTION OF REPERFUSION 
 Sudden disappearance of chest pain is associated with 
successful thrombolysis. But this is difficult to assess in the 
CCU setup when most of the patients receive opioid analgesics.  
ECG : A BETTER PREDICTOR OF PERFUSION AT 
MICROVASCULAR LEVEL 
 Recent studies have suggested that achievement of TIMI 
grade 3 flow in infarct related artery is not in itself indicative of 
successful myocardial reperfusion18. 
 Myocardial contrast echocardiography has shown that 
even in the presence of normal epicardial flow after PTCA, 
impaired myocardial perfusion at tissue level can occur and is 
associated with poor recovery of LV function. 
 Resolution of ST-segment elevation on the surface ECG 
correlated closely with findings at contrast echocardiography18. 
Less than 50% resolution of ST-segment elevation in the chest 
lead and no accelerated idioventricular rhythm has a sensitivity 
of 81%. Specificity of 88% and overall accuracy of 85% in 
predicting < TIMI 3 flow in infarct related vessels20. 
PROGNOSTIC SIGNIFICANCE   OF ST RESOLUTION 
 James A-de-Lemos et al. reported that 30 days mortality 
was 2.4% among patients who attain < 70% ST resolutions at 
90 minutes where as it was 8.1% in those with < 30% ST 
resolution21. 
 Early and stable ST segment recovery is also associated 
with improved infarct zone wall motion at 48 hours22. 
FACTORS INFLUENCING THE SUCCESS OF THROMBOLYSIS 
1. Time interval between pain onset to initiation of 
thrombolytic therapy 
 This is the most important variable affecting the success 
of thrombolysis. 
 As time window broadens not only more and more 
myocardium gets necrosed but also the thrombus gets 
organized and become more  resistant to lysis.  
2. Structure of thrombi 
 Thrombi rich in platelets are more resistant to lysis than 
fibrin rich thrombi. 
3. Circadian fluctuations 
 A morning resistance to thrombolytic therapy was 
observed by Braunwald et al.23. where as better success rate of 
thrombolysis was found by E Gold Hammer et al. when SK was 
administered between 16.00-20.00 hours. 
4. Pre  infarction Angina 
 Patients with acute myocardial infarction who have 
intermittent infarct related pain or unstable angina in the seven 
days preceding the infarction have faster coronary artery 
perfusion and smaller infarcts after thrombolytic therapy than 
patients without pre infarction angina24. 
 This may be an additional mechanism for the better 
prognosis in these patients, the other proposed mechanism 
being ischemic preconditioning.  
5. Sex 
 Even though mortality is high among women who develop 
acute myocardiac infarction. Compared to men, the rate of 
induction of coronary patency with thrombolytic drugs are 
comparable in women. 
 Menstruation is not a contraindication for thrombolysis 
therapy because menstrual bleeding is related more to 
sloughing of tissue than active bleeding.   
6. Congestive heart failure and cardiogenic shock 
          No significant reduction in mortality occurs when Killip 
class IV patients are treated with SK. This may partly be due to 
low rate of adequate recanalisation. 
7. Elderly patients 
 Risk of hemorrhagic complications are high in those aged 
above 75 years. But the relative benefit seen with coronary 
thrombolysis is greatest for the elderly.  
REPERFUSION INJURY 
 Refers to detrimental metabolic, functional or structural 
consequence of restoring coronary flow that might be reduced, 
avoided or reversed by modifying the condition of reperfusion.  
LETHAL REPERFUSION INJURY 
 Refers to the death of myocardium that were still alive at 
the initiation of reperfusion. The mechanisms underlying the 
lethal reperfusion injury may be. 
1. Ischemia causes an intracellular osmotic load of 
accumulated metabolites like lactate inside the cardiac 
myocytes leading to an increase in the osmolality of 
cytosol. After reperfusion enough plasma water bathes 
these cells. Osmotic diffusion of water into the cell causes 
rupture of cells.  
2. Cellular acidosis increases the intracellular excess of 
calcium, via Na-H+ exchange and Ca-Na+ exchange. This 
calcium overload causes myofibrillar hypercontraction 
and rupture of sarcolemma. 
3. Excess free radical formation may damage the myocyte 
structure including sarcolemma. 
NON LETHAL REPERFUSION INJURY 
Stunning 
 It is a form of reversible post ischemic contractile 
dysfunction. 
Reperfusion arrhythmia 
 It also considered a form of non lethal reperfusion injury. 
EFFECT OF REPERFUSION ON INFARCT REPAIR 
 Clinical studies has revealed that thrombolytic 
reperfusion performed more than 6 hours after symptom onset 
could still improve ventricular function and survival even 
though myocardial salvage need not be responsible for this 
effect.  
 This has been attributed to faster healing, reducing the 
complication like infarct expansion, aneurysm, as well as 
cardiac rupture.  
 Reperfusion gives inflammatory cells access to the 
infracted region, with resultant degradation of dead cells which 
must be removed in order for repair to occur. 
PATIENTS AND METHODS 
PLACE OF STUDY 
 This study was conducted in the coronary care unit of 
Government Royapettah Hospital, Chennai. 
PERIOD OF STUDY 
 From January  2005 to August 2005. 
DESIGN 
 Observational prospective cohort study of patients 
receiving streptokinase for acute myocardial infarctions. A total 
of 115 patients were included in the study. 
METHODOLOGY 
A. Subject selection 
1. Inclusion criteria 
 a. Presence of typical chest pain suggestive of Acute 
myocardial infarction along with ECG evidence of Acute 
myocardial infarction. Criteria for thrombolysis being 2mm or 
more ST elevation in two contiguous pericardial leads or 1mm 
or more ST elevation in two contiguous limb leads. ECG were 
recorded using Hewlett. Packard Page write 100 machine.  
 b. Time window of 12 hrs from the onset of pain to the 
initiation of thrombolysis. 
2. Exclusion criteria 
 a. Late thrombolysis (more than 12 hrs from the onset 
of pain) 
 b. Recurrent myocardial infarction 
 c. Presence of bundle branch block 
 d. Development of pericarditis 
DRUG THERAPY 
 All patients received streptokinase 1.5 million units in 
100ml of normal saline over 60 minutes. 
 Aspirin was given to all patients. 
 Use of heparin, β blockers, ACE inhibitors was according 
to CCU protocols, which was in accordance with 
ACC/AHA recommendations. 
CRITERIA FOR SUCCESSFUL THROMBOLYSIS 
Success was defined by 
 Clinical complete subsidence of chest pain. 
 Electrocardiographically – more than 50% ST resolution in 
a lead which showed maximum ST elevation initially. ST 
Elevation is measured manually, 80ms after J point from 
isoelectric line. Preceding PR segment is taken as isoelectric 
line. 
Patients were analysed for success at thrombolytic 
therapy at 90 minutes after initiation of thrombolytic therapy, 
applying the above mentioned criteria.  
The following parameters were analysed among them to 
know whether they influenced the outcome of thrombolysis. 
 Age 
 Sex 
 Body mass index 
 Smoking status 
 Alcohol intake 
 Diabetes mellitus 
 Systemic hypertension 
 Pre infarction Angina 
 Time window 
 Location of myocardial infarction 
DEFINITIONS 
Body Mass Index  
     Weight (kg) 
 BMI  =  
    Height 2 (meter) 
 
S.No. 
Body Mass Index 
(Kg/m2) 
Grade 
1. < 18.5  Under weight 
2. 18.5 to 24.9 Normal weight 
3. 25.0 to 29.9 Over weight 
4. 30.0 to 34.9 Class 1  Obesity  
5. 35.0 to 39.9 Class II  Obesity 
6. ≥ 40.0  Class III   Obesity 
 A BMI between 25 and 30 should be viewed as medically 
significant and worthy of therapeutic intervention, especially in 
the presence of risk factors that are influenced by adiposity, 
such as hypertension and glucose intolerance. 
Smoking 
 Patients are considered smokers if they were using 
tobacco for smoking in any form currently. Ex. Smoker were 
defined as those who quitted smoking for more than 1 year 
back from the date of admission. 
Diabetes mellitus 
 Patients were considered to be diabetic when 
1. Currently on oral hypoglycemic drugs and/or insulin 
or 
2. Fasting plasma glucose > 126 mg% or 2 hr post 
prandial plasma shows > 200mg on more than 2 
occasions.  
Hypertension 
 Patients were considered hypertensives when 
 They are already on antihypertensive medications 
 Medically documented history of blood pressure elevation 
more than 140/90 mmHg, on two occasions in the past.  
Pre infarction angina 
 Was defined as history of anginal pain during the 
preceding 7 days of the active event causing hospital admission.  
Location of myocardial infarction 
Inferior wall infarction 
 Patients with ST elevation, with or without Q wave in 
Leads II; III; aVF are considered to have inferior wall infarction. 
Anterior wall infarction 
 Those people showing ST elevation with or without Q wave 
in any two contiguous leads from V1-V6 and L1 and aVL are 
considered to have anterior wall infarction.   
FOLLOW UP 
 Patients were followed by until they were discharged from 
the hospital. ECHO was done whenever possible.  
STATISTICAL METHOD 
 Univariate analysis was done by chi-square test and 
multivariate analysis by logistic regression, was done using 
SPSS windows computer software.  
  
OBSERVATIONS 
A total of 115 patients were studied. Their age ranged 
from 31-76 years (mean 53.44). 94 of them were males (81.74%) 
and 21 females (18.26%). 60 of them were hypertensives 
(52.17%) 46 were diabetic (40%). 67 people   were smokers 
(58.26%) and 38 (33.04) used to consume alcohol. 68 (59.13%) 
of them were overweight  
BMI ≥ 25. 28 patients experienced pre infarction angina 
(24.35%). 66 patients had anterior wall infarction  (57.39) and 
49 patients (42.61) had inferior infarction.  
DETAILS OF STUDY POPULATION 
Total Number of Patients  - 115 
  
TABLE – 1 
SEXWISE DISTRIBUTION  
S.No. Sex Number Percentage 
1. Male 94 81.74% 
2. Female  21 18.26% 
 
 
 
 
 
SEXWISE DISTRIBUTION
Male
82%
Female
18%
  
 
 TABLE – 2 
AGEWISE DISTRIBUTION  
S.No. Sex Number Percentage 
1. < 60 years 76 66.09% 
2. ≥ 60 Years 39 33.91% 
 
 
 
 
AGEWISE DISTRIBUTION
< 60 years
66%
> 60 Years
34%
 
 TABLE – 3 
SOCIO ECONOMIC STATUS  
S.No. Family Income Number Percentage 
1. < 1500 71 61.74% 
2. 1501 – 3000 40 34.78% 
3. 3001 – 5000 4 3.48% 
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 TABLE – 4 
BODY MASS INDEX 
S.No. 
BMI 
(Kg / M2) 
Number Percentage 
1. < 24.9 47 40.87% 
2. ≥ 25 68 59.13% 
 
BODY MASS INDEX
< 24.9
41%
> 25
59%
 
TABLE – 5 
RISK FACTORS  
S.No. Risk Factors  Number Percentage 
1. Smoking 67 58.26% 
2. Alcohol 38 33.04% 
3. Diabetes 46 40% 
4. Hypertension 60 52.17% 
5. Pre infarction angina  28 24.35% 
 
0
10
20
30
40
50
60
Pe
rc
en
ta
ge
 
o
f C
as
es
Smoking Alcohol Diabetes Hypertension Pre infarction
angina
RISK FACTORS
 TABLE – 6 
TIME WINDOW 
S.No. Time Window Number Percentage 
1. 0-4 hours  64 55.65% 
2. 4-8 hours 33 28.70% 
3. 8-12 hours 18 15.65% 
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 TABLE – 7 
LOCATION OF MYOCARDIAL INFARCTION 
S.No. Myocardial infarction  Number Percentage 
1. Anterior wall infarction 66 57.39% 
2. Inferior wall infarction  49 42.61 
 
LOCATION OF MYOCARDIAL INFARCTION
Inferior Wall 
Infarction
43%
Anterior Wall 
Infarction
57%
 
CLINICAL DETAILS OF STUDY POPULATION ACCORDING 
TO THE OUTCOME OF THROMBOLYSIS 
Variables Success Failure 
Number 78 (67.83%) 37 (32.17%) 
SEX   
 Male 
 Female 
66 
12 
28 
9 
AGE   
 < 60 years 
 ≥  60 years 
52 
26 
24 
13 
BMI  (Kg / m2)   
 < 24.9 
 ≥ 25 
45 
33 
2 
35 
Smoking 
Alcohol 
Diabetes 
Hypertension 
Pre  infarction Angina 
39 
28 
20 
37 
19 
28 
10 
26 
23 
9 
TIME WINDOW   
 0 – 4 hours 
 4 – 8 hours 
 8 – 12 hours 
51 
20 
7 
13 
13 
11 
LOCATION OF MI   
 Anterior wall infarction 
 Inferior wall infarction 
  
36 
42 
30 
7 
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SUCCESS RATE WITH RESPECT TO INDIVIDUAL 
VARIABLES
Total Number Success
 OUTCOME OF THROMBOLYSIS 
(Total No. of Patients 115)
Success
68%
Failed
32%
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SUCCESS RATE OF THROMBOLYSIS IN ANTERIOR AND 
INFERIOR INFARCTIONS 
 
ANTERIOR WALL INFARCTION
Success
55%
Failure
45%
 
 
INFERIOR WALL INFARCTION
Success
86%
Failure
14%
 
 
 UNIVARIATE ANALYSIS FOR INFLUENCING  
FACTORS 
Sl. 
No. 
Variable 
Odds 
Ratio 
X2 chi-
square 
P 
value 
Comment 
1. Gender 0.57 1.34 0.57 Not 
Significant  
2. Age 1.08 0.04 0.848 Not 
Significant 
3. BMI 23.86 28.39 0.000 Significant 
4. Smoking 3.11 6.80 0.009 Significant 
5. Alcohol 0.66 0.89 0.345 Not 
Significant 
6. Diabetes 6.85 26.83 0.000 Significant 
7. Hypertension 1.82 2.18 0.139 Not 
Significant 
8. Pre infarction 
Angina  
1.00 0.00 0.996 Not 
Significant 
9. Time Window 
 0-4 hours 
 4-8 hours 
 
 8-12 hours 
 
0.29 
1.57 
 
4.29 
 
9.30 
1.11 
 
8.19 
 
0.002 
0.290 
 
0.004 
 
Significant 
Not 
Significant 
Significant 
10. Location of 
myocardial 
infarction 
    
  Anterior  wall    
 Inferior wall  
5.00 
0.20 
12.52 0.004 Significant 
 
MULTIVARIATE ANALYSIS OF COMBINATION OF FACTORS 
INFLUENCING THE OUTCOME OF THROMBOLYSIS  
We have individually tested the variables with outcome. 
Since we have multiple variables we have used logistic 
Regression Analysis for testing the significance of combination 
of variables with outcome. 
LOGISTIC REGRESSION ANALYSIS 
S.No. Variable 
Significant 
(P Value) 
Odds ratio 
(Multivariate) 
1 BMI  ≥  25 0.001 33.049 
2 Smoking 0.000 0.071 
3 Diabetes 0.001 12.206 
4 Time Window (4 to 12 
hrs) 
0.072 3.112 
5 Anterior wall infarction  0.001 0.067 
 
 We have found only the above five variables were 
statistically significant in deciding the outcome of the 
thrombolysis. Of these patient with BMI ≥ 25 have 33 times 
more chance of failure than patient with BMI < 24.9. Diabetes 
have 12 times more chance of failure than non diabetics. 
Patients presented late > 4 hrs have 3 times chance of failure 
than those presented ≤ 4 hrs. 
 DISCUSSION 
 The major finding of this study is that the location of the 
infarct significantly affects the outcome of thrombolysis. Those 
with anterior wall myocardial infarction have a 5 times chance 
of undergoing failure of thrombolysis compared to inferior wall 
myocardial infarction (P=0.004) This is after adjustment for all 
confounding variables like time window, age, smoking status, 
index, diabetes and hypertension. 
 Similar25 observations were made by Gibson, Murphy and 
Braunwald et al. (TIMI Study group).  Then found that TIMI 
grade III flow rates were lower for left coronary and circumflex 
artery compared to right coronary artery after thrombolytic 
therapy.  
 The reason for this differential response will be evident 
when we look into physiology of coronary circulation in right 
and left coronary arteries. 
 Blood flow in right coronary artery is relatively 
independent of phases of cardiac cycle, being present in both 
systole and diastole. Where as flow in left coronary artery is 
almost absent during systole and may even be reversed in 
conditions of heightened microvascular tone and left ventricular 
hypertrophy26. 
 The relatively thicker wall, the increased wall thickening 
during systolic contraction and higher intracavitary pressure of 
left ventricle may all produce higher intramyocardial pressure 
that is observed in the thinner walled right ventricle, which is 
also subjected to lower filling pressures.  
 Moreover the extent of necrosis in anterior wall is more 
resulting in increased myocardial edema compared to inferior 
infarctions. This may further decrease the reperfusion rates in 
anterior infarctions. Yet another mechanism may be, better 
drug delivery to right coronary artery and prolonged contact of 
streptokinase with the thrombus, resulting in more efficient 
fibrinolysis.  
ALCOHOL AND THROMBOLYSIS 
 Alcohol consumption has no influence in the outcome of 
thrombolytic therapy in our study. OR = 0.66, X2= 0.89, P= 
0.345, which is statistically not significant.  
Alcohol is known to reduce coronary artery disease related 
mortality. In a meta analysis of all experimental studies that 
assessed the effects of moderate alcohol intake on 
concentrations  of HDL cholesterol, apolipoprotein A1, 
fibrinogen, triglycerides and other biological markers, Rimm, 
William, Fosher et al.27. Concluded that 30g of alcohol per day 
would cause an estimated reduction of 24.7% in risk of 
coronary artery disease.  
INFLUENCE OF AGE OF THE PATIENT ON THROMBOLYSIS 
 Age has got no influence in the outcome of thrombolysis 
in our study X2=0.04, OR=1.08, P= 0.848, which is statistically 
not significant.  
 This shows that with respect to fibrinolysis elderly people 
do not behave differently from younger people. This is reflected 
in reduction mortality rate among elderly with thrombolysis. In 
patients aged more than 75 years who were treated with 
streptokinase in GISSI-2 trial, there was a reduction of 4.2 
fewer deaths per 100 patients than in controls. In ISIS-2 there 
was 3.3 fewer deaths per 100 patients in those over 70 years of 
age who were treated4. 
GENDER 
 No statistically significant difference was noticed based on 
gender. Wood field, Lunderberg, Topol et al.30, performed as 
angiographic study to findout the patency rate at 90 minutes in 
men versus women. 
 At 90 minutes TIMI-3 flow rate was 39% in women and 
38% in men, which was not statistically significant. But 30 day 
mortality was 13.1% in women versus 4.8% in men (p= 0.001) 
 Thus even though females have a poor outcome after 
myocardial infarction, they do not behave differently to 
thrombolytic therapy.  
BODY MASS INDEX  
 Patients with BMI ≥ 25 have more chance of failure of 
thrombolysis than patient with BMI < 24.9.  OR = 23.86,  X2 = 
28.39,  P = 0.000 which is statistically highly significant.  
 Similar observations made by Lundergan CF, Reiner JS, 
McCathy WF, et al. They described the increasing the body 
weight is associated with a reduced likelihood of successful 
(TIMI grade 3 flow) infarct related artery reperfusion 90 minutes 
after thrombolysis35.  
  The higher the BMI group, the higher the prevalence of 
hypertension, diabetes mellitus, history of familial coronary 
disease and hyperlipidemia. 
DIABETES MELLITUS 
 In this study success rate of thrombolysis in diabetics is 
found to be different from non diabetic population.Univariate 
analysis shows Odds ratio=6.85,X2=26.83,P value=0.000, 
which is statistically significant. 
 Gray, Yudkin et al. found a reduction in reperfusion rates 
in thrombolysed diabetic patients31. 
 Diabetes is a prothrombotic state as reflected by the 
increased blood levels of fibrinogen, factor VII, and Von 
Willebrand factor. These changes are even more increased if 
diabetic people happened to be smokers.  
 Platelet function is also impaired in diabetics. They 
aggregate more readily to stimuli like ADP and collagen. 
Glycation of membrane proteins due to chronic exposure to 
high blood glucose levels32, change in fluidity of platelet 
membrane brought out by high concentration of cholesterol and 
triglycerides are the proposed mechanisms for these 
abnormalities.  
 On the otherhand patients with type II diabetes have 
profound suppression of fibrinolysis. Plasminogen activator 
inhibitor-1 levels are high in type II diabetic people which is 
responsible for this effect. 
 Nevertheless thrombolytic therapy should be administered 
to diabetics with Acute myocardial infarction, because for every 
100 diabetic patients treated with thromoblytic drugs four lives 
are saved. 
PRE INFARCTION ANGINA 
 Andreoti; Vincenzo et al. had demonstrated by 
angiographic method that those acute myocardial infarction 
patients who experienced preinfarction angina within seven 
days preceding the acute event had a more rapid thromoblysis. 
Potency rates were higher at 35 minutes but at 90 minutes 
both were same33. 
 In this study success rate was same at 90 minutes in 
both groups. This is because ECG monitoring was not 
continuous in this study. Continuous ST segment monitoring 
may be needed to demonstrate the early achievement of patency 
in pre infarction angina patients.  
SMOKING 
 Outcome of thrombolysis is affected by smoking. In this 
study there is a statistically significant trend towards a bad out 
come34.  Odds ratio=3.11,X2=6.80,P=0.009 which is statistically 
significant. Smoking increases blood hematocrit, fibrinogen 
levels and platelet levels contributing to the hypercoagulable 
state promoting coronary thrombosis, smokers are also found 
to have lesser fibrinolytic activity than non smokers.  
CIRCADIAN VARIATION 
 Eugene23 Braunwald et al.  noticed a circardian variation 
in efficacy of thrombolytic therapy, with better patency rates in 
the evening hours. This is due to circadian variation in the 
blood levels of PAI-1, which is highest in the morning hours.  
 In this study no such circadian variation was observed. 
Probable reasons for this discrepancy may be the shorter time 
window observed in patients presenting in morning homes as 
well as smaller sample size. 
PAIN TO STREPTOKINASE INTERVAL (TIME WINDOW) 
 This is the most powerful predictor of success rate. In this 
study also it is evident. Success rate was 55.65% those patients 
thromoblysed within 4 hrs from the onset of symptoms, the 
success rate decreased to 28.70% when they were 
thrombolysed after 4 hrs but within 8 hrs of onset of symptoms. 
Success rate came down to 15.65% when streptokinase was 
administered after 8 hours but within 12 hours.  
 CONCLUSION 
 In this study the overall success rate of thrombolysis 
was 68% 
 Age, Gender, Alcohol intake, Hypertension, pre 
infarction Angina have no influence in the outcome of 
thrombolysis. 
 Patient with BMI ≥ 25, Smoking, Diabetes were affect 
the outcome of thrombolysis in unfavourable way. 
 Pain to streptokinase interval (Time Window) affect the 
outcome of thrombolysis in favourable way. Earlier 
they came, they had better outcome. 
 Anterior wall myocardial infarction 5 times more 
chance of failure than inferior wall myocardial 
infarction. 
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PROFORMA 
        Case No. 
Name  :   Age :  Sex : 
IP No. :   DOA  :  ICCU No. : 
Address :      Occupation : 
 
PRESENTING HISTORY 
Anginal Chest Pain  Radiation   Dyspnea  
Atypical Chest Pain  Sweating  Syncope   
Palpitations    Fatigability     Cold Extremities
   
Others     
 
PREVIOUS & PERSONAL HISTORY 
IHD  HTN  DM  COPD/BA  Alcohol  
Smoking   Hypercholesterolemia      Others   
 
EXAMINATION 
Cold Peripheries   Pedal Odema    Cyanosis   
BMI  < 24.9    ≥ 25   
PR :   BP :   JVP : 
 
CVS : S1S2     LV  S3/S4   
  RV S3/S4    Others   
RS  :  Breath Sounds   Rhonchi   
  Basal Creps    Others 
  
  Emphysematous changes  
      
 
 ABDOMEN : 
  Hepatomegaly   
CNS : 
Signs of Cardiac Failure  : 
 Killip Stage  : 
Investigations   : 
Blood Sugar   :   SGOT  : 
Serum Cholesterol  :   CXR PA : 
 
ECG : 
Admission ECG : 
90 min ECG after Inj. SK : 
ST. Resolution < 50%  
   > 50%  
 
Pain reduction after Inj. SK  : Yes    No  
Echo : 
 
Outcome : 
 Successful   
 Failed    
 
 
 
 
 
MASTER CHART 
Time Window Type of MI S.  
No. IP No. Age Sex 
Socio 
Economic 
status 
BMI Smoking Alcohol DM HT Preinfarction Angina 0-4 Hrs. 
4-8 
Hrs. 
8-12 
Hrs. AWMI IWMI 
Outcome 
1 807402 48 M 1 21.9 1 0 0 0 0 1 0 0 1 0 1 
2 807569 78 M 1 24.6 0 0 1 1 0 0 1 0 0 1 0 
3 807600 48 M 1 23.8 1 0 1 0 1 1 0 0 0 1 0 
4 807771 81 M 2 22.7 0 0 0 0 0 1 0 0 0 1 0 
5 807772 30 M 1 24.3 1 0 1 0 1 0 1 0 1 0 0 
6 807974 42 M 2 31.3 1 1 0 0 1 0 1 0 1 0 1 
7 808064 52 M 1 25 1 0 0 0 0 1 0 0 1 0 0 
8 807984 52 F 1 27.3 0 0 1 1 0 0 1 0 0 1 0 
9 808411 60 F 1 24.8 0 0 0 0 0 1 0 0 0 1 0 
10 808481 62 M 2 30.3 1 0 0 1 0 0 0 1 1 0 1 
11 808492 60 M 2 32.8 1 0 0 0 1 1 0 0 0 1 0 
12 808596 55 F 1 28 0 0 1 1 0 1 0 0 1 0 1 
13 808730 54 M 1 27 1 1 1 0 0 0 1 0 1 0 1 
14 809025 60 F 1 24.2 0 0 0 1 0 0 1 0 1 0 0 
15 809026 65 M 2 33.8 1 1 0 0 1 1 0 0 1 0 0 
16 809137 68 M 1 34 1 1 1 0 0 1 0 0 0 1 1 
17 809146 54 F 2 34.6 0 0 1 0 0 0 1 0 1 0 1 
18 809289 50 M 2 36.5 1 0 0 1 0 1 0 0 1 0 1 
19 809349 60 M 1 28.3 1 0 1 1 0 1 0 0 0 1 0 
20 809360 56 M 2 23.8 1 0 0 1 1 1 0 0 0 1 0 
21 809681 62 M 1 24.9 1 1 0 0 0 0 1 0 0 1 0 
22 809779 53 F 1 30 0 0 1 0 0 0 1 0 0 1 0 
23 809980 46 M 1 27.7 1 1 0 1 0 1 0 0 1 0 0 
24 809984 48 M 1 24.1 1 0 0 1 0 0 1 0 0 1 0 
25 810026 50 M 2 26.9 0 1 1 0 0 0 0 1 1 0 0 
26 810139 60 M 1 22 0 0 0 1 0 1 0 0 1 0 0 
27 810163 40 M 2 32.4 1 0 1 1 0 0 1 0 1 0 1 
28 810176 45 M 1 23 1 1 0 0 0 1 0 0 1 0 0 
29 810260 49 M 2 31.5 0 0 0 0 0 1 0 0 1 0 0 
30 810288 58 M 1 23.9 0 1 0 1 0 0 1 0 0 1 0 
31 810575 58 M 2 26 1 0 0 1 0 1 0 0 0 1 0 
32 810585 55 M 1 26.4 0 1 0 0 0 0 1 0 1 0 0 
33 810684 61 M 1 23.9 0 0 0 1 0 1 0 0 0 1 0 
34 810857 50 M 3 28.8 1 1 0 1 0 1 0 0 0 1 0 
35 810870 44 M 1 24.4 1 1 0 0 0 1 0 0 0 1 0 
36 811042 43 F 1 26.7 0 0 0 1 0 0 1 0 1 0 0 
37 811138 68 F 1 25.6 0 0 0 0 0 1 0 0 1 0 0 
38 811542 47 M 2 34.6 1 1 1 1 0 1 0 0 1 0 1 
39 811630 57 M 1 24.8 0 0 0 1 0 1 0 0 1 0 0 
40 811748 36 F 2 37.7 0 0 1 1 0 0 1 0 1 0 1 
41 812044 60 M 2 36.3 1 1 0 1 0 0 0 1 1 0 1 
42 812104 38 M 1 24.8 0 0 0 0 0 0 1 0 1 0 0 
43 812402 43 M 2 25 1 0 0 0 0 1 0 0 0 1 0 
44 812455 60 M 1 24.8 0 0 0 1 0 1 0 0 1 0 0 
45 812459 49 M 1 26.2 0 0 0 0 0 0 1 0 1 0 0 
46 812582 71 M 3 38 1 1 1 1 1 1 0 0 0 1 1 
47 812586 45 M 2 31 0 0 0 0 0 0 1 0 1 0 0 
48 812661 50 M 3 24 1 0 0 1 0 1 0 0 0 1 0 
49 812786 54 M 1 27 0 0 0 0 0 0 1 0 1 0 0 
50 812911 65 M 2 36.3 1 1 1 1 0 0 1 0 0 1 1 
51 812961 60 M 2 29 0 0 0 0 0 1 0 0 1 0 0 
52 813053 63 M 2 26.4 0 0 0 1 0 1 0 0 0 1 0 
53 813211 40 M 1 24.7 0 1 0 0 0 0 1 0 1 0 0 
54 813146 40 M 1 23.8 0 0 0 1 0 1 0 0 1 0 0 
55 813204 52 M 1 34.3 1 0 1 1 0 0 0 1 0 1 1 
56 813284 32 M 2 31 0 1 0 1 0 0 1 0 1 0 0 
57 813361 60 F 2 38.9 0 0 1 0 0 0 0 1 0 1 1 
58 813529 55 M 1 24.1 0 1 0 1 0 0 1 0 1 0 0 
59 813619 57 M 1 33 1 1 1 1 1 1 0 0 0 1 0 
60 813696 60 F 1 28 0 0 1 1 1 1 0 0 0 1 0 
61 813800 38 M 1 24.4 1 1 0 1 1 1 0 0 0 1 0 
62 813820 52 M 2 34.2 1 0 0 1 1 1 0 0 1 0 1 
63 813815 72 F 2 37 0 0 1 1 0 0 1 0 1 0 1 
64 813828 72 M 2 34.5 1 0 1 1 1 0 0 1 1 0 1 
65 814140 60 M 1 23 1 1 0 1 1 1 0 0 1 0 0 
66 814165 40 M 2 28 1 0 1 0 0 1 0 0 1 0 1 
67 814263 49 M 1 27.3 1 1 0 0 0 1 0 0 0 1 0 
68 814301 60 M 2 35 1 0 1 1 0 0 1 0 0 1 1 
69 814364 50 F 2 28.6 0 0 0 1 1 0 0 1 1 0 1 
70 814424 48 M 2 27.5 1 0 1 0 0 1 0 0 1 0 1 
71 814624 40 M 2 23.9 1 1 0 0 0 1 0 0 0 1 0 
72 814648 48 M 3 24.9 1 1 0 1 1 1 0 0 0 1 0 
73 814653 50 M 1 31 1 1 0 1 0 1 0 0 1 0 0 
74 814686 44 F 1 36 0 0 1 0 0 0 1 0 1 0 1 
75 815074 42 M 2 31.4 1 0 1 0 0 0 0 1 1 0 1 
76 815092 64 M 1 24.6 1 1 0 0 1 1 0 0 1 0 0 
77 815205 68 F 2 30.5 0 0 1 1 0 1 0 0 1 0 0 
78 815094 78 F 1 31 0 0 0 1 0 1 0 0 0 1 0 
79 815291 55 F 2 29.3 0 0 1 0 1 1 0 0 1 0 1 
80 815319 44 M 1 23 1 1 0 0 0 0 1 0 0 1 0 
81 815332 42 M 1 24.3 1 0 0 1 0 1 0 0 0 1 0 
82 815555 64 M 2 32.4 1 0 1 0 1 0 1 0 1 0 0 
83 815706 68 M 1 24 1 1 0 1 0 1 0 0 1 0 0 
84 815782 65 F 2 33 0 0 0 1 0 0 0 1 0 1 0 
85 815783 52 M 1 24.3 1 0 1 0 1 0 0 1 0 1 0 
86 815813 77 M 1 24.7 0 1 0 0 0 1 0 0 1 0 0 
87 815936 49 M 1 33 1 0 0 1 0 0 1 0 1 0 1 
88 816013 42 M 1 26 1 0 1 1 1 0 0 1 0 1 0 
89 816031 82 M 1 33 0 1 1 0 0 1 0 0 0 1 0 
90 816242 50 M 2 32.6 1 0 0 1 1 0 0 1 1 0 1 
91 816463 44 M 1 23.7 0 0 0 0 0 1 0 0 0 1 0 
92 816942 55 M 1 32 1 1 0 1 0 1 0 0 1 0 1 
93 816977 45 M 1 24.3 1 0 1 0 1 1 0 0 1 0 0 
94 817082 50 M 1 34.7 1 0 0 1 1 0 1 0 1 0 1 
95 817131 60 M 1 37 1 0 1 0 0 0 0 1 1 0 1 
96 817135 46 M 1 36.7 1 0 1 1 1 1 0 0 0 1 1 
97 817194 50 M 1 27.5 1 1 1 1 0 0 1 0 1 0 1 
98 817200 55 M 1 24.1 1 0 0 0 0 1 0 0 0 1 0 
99 817218 47 M 1 23.8 1 0 1 1 1 0 0 1 0 1 0 
100 817615 41 M 1 24.7 1 0 1 1 0 1 0 0 1 0 0 
101 818019 57 M 1 24.2 1 0 0 0 0 1 0 0 0 1 0 
102 818109 60 M 2 36 1 1 1 1 0 0 0 1 1 0 1 
103 818140 60 M 1 22.7 1 0 0 0 0 1 0 0 0 1 0 
104 818312 61 M 1 24 1 0 1 0 0 1 0 0 1 0 1 
105 818321 31 M 1 22 0 1 0 0 0 1 0 0 1 0 0 
106 818338 60 F 2 31 0 0 1 0 0 0 1 0 1 0 1 
107 818584 48 M 2 30.9 1 0 1 1 0 0 0 1 1 0 1 
108 818580 52 M 1 23.9 0 0 0 1 0 1 0 0 1 0 0 
109 818730 55 M 1 29.2 1 1 0 0 1 0 0 1 0 1 0 
110 818821 45 M 1 22.9 1 0 1 0 0 1 0 0 0 1 0 
111 818862 35 M 1 24.1 0 1 0 0 0 0 1 0 0 1 0 
112 819071 51 M 1 24.5 1 0 0 0 1 1 0 0 1 0 0 
113 819364 44 M 1 28.6 0 1 1 1 0 1 0 0 0 1 0 
114 819376 50 F 1 24.6 0 0 0 0 0 0 0 1 0 1 0 
115 819563 60 F 2 32.3 0 0 1 1 1 1 0 0 1 0 0 
 Socio economic Status  :  1 - Income < 1500;  2 - Income 1501 - 3000;   3 - Income 3001 - 5000 
Smoking :  0 - No;   1 - Yes 
Alcohol   :  0 - No;   1 - Yes 
Diabetes :  0 - No;   1 - Yes 
Hypertension :  0 - No;   1 - Yes 
Pre-infarction angina  : 0 - No;  1 - Yes 
Time Window :  0 - No;   1 - Yes 
Type of MI  : 0 - No;  1 - Yes 
Outcome  : 0 - Successful;  1 -  Failed 
M - Male 
F - Female 
 
